Clinical Trial Update: A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy [Phase 2, Phase 3]

View source ↗

Summary

This is a Phase 2/3 clinical trial evaluating BHV-7000 for safety and efficacy in adults with refractory focal onset epilepsy; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Epilepsy

Drugs mentioned

• BHV-7000

Snippet

Sponsor: Biohaven Therapeutics Ltd. | Conditions: Focal Epilepsy | Phase 2, Phase 3 | Status: RECRUITING